Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.54 USD -3.14% Market Closed
Market Cap: 408.7m USD

Akebia Therapeutics Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Akebia Therapeutics Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Akebia Therapeutics Inc
NASDAQ:AKBA
Interest Income Expense
-$26.2m
CAGR 3-Years
-11%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2.6B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$694m
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-30%
CAGR 5-Years
-25%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$476.3m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

Akebia Therapeutics Inc
Glance View

Market Cap
408.4m USD
Industry
Biotechnology

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

AKBA Intrinsic Value
3.43 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is Akebia Therapeutics Inc's Interest Income Expense?
Interest Income Expense
-26.2m USD

Based on the financial report for Sep 30, 2025, Akebia Therapeutics Inc's Interest Income Expense amounts to -26.2m USD.

What is Akebia Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-29%

Over the last year, the Interest Income Expense growth was -106%. The average annual Interest Income Expense growth rates for Akebia Therapeutics Inc have been -11% over the past three years , -29% over the past five years .

Back to Top